Genmab, Novartis sales and marketing update

The U.K.’s NICE issued final guidance recommending Arzerra ofatumumab ( HuMax-CD20) from Novartis with chlorambucil to treat untreated chronic lymphocytic leukemia (CLL). Arzerra is recommended only when treatments containing fludarabine and bendamustine are unsuitable and if the pharma provides the human mAb against CD20 at an undisclosed discount under a patient access scheme. The final guidance is in line with a March final appraisal determination (FAD). Arzerra is approved in the EU in combination with chlorambucil or bendamustine for untreated CLL in patients who are ineligible for fludarabine-based therapy. ...